Sei Investments Co. Boosts Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Sei Investments Co. lifted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 14.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 339,461 shares of the company's stock after purchasing an additional 42,743 shares during the quarter. Sei Investments Co. owned 0.11% of Amneal Pharmaceuticals worth $2,689,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its stake in Amneal Pharmaceuticals by 149.7% in the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock worth $10,792,000 after purchasing an additional 777,568 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Amneal Pharmaceuticals by 11.1% during the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock valued at $31,511,000 after buying an additional 378,136 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth about $2,946,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Amneal Pharmaceuticals by 16.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company's stock valued at $11,689,000 after acquiring an additional 202,863 shares during the last quarter. Finally, Barclays PLC boosted its holdings in Amneal Pharmaceuticals by 134.1% during the 3rd quarter. Barclays PLC now owns 296,384 shares of the company's stock valued at $2,466,000 after acquiring an additional 169,756 shares during the period. 31.82% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Gautam Patel sold 80,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the transaction, the director now directly owns 1,808,886 shares in the company, valued at $16,099,085.40. This trade represents a 4.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the transaction, the insider now directly owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. This trade represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,160,000 shares of company stock valued at $43,113,200 over the last three months. Corporate insiders own 26.56% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $9.00 to $12.00 in a research report on Monday, February 24th. StockNews.com lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. Finally, Barclays raised their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $10.80.

Amneal Pharmaceuticals Stock Performance

Shares of Amneal Pharmaceuticals stock traded up $0.44 during midday trading on Wednesday, reaching $7.43. 3,134,203 shares of the company's stock traded hands, compared to its average volume of 1,397,478. The stock has a 50 day moving average of $8.22 and a 200-day moving average of $8.30. Amneal Pharmaceuticals, Inc. has a 12 month low of $5.18 and a 12 month high of $9.48. The company has a market cap of $2.30 billion, a PE ratio of -10.93 and a beta of 1.06.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. During the same quarter last year, the company posted $0.14 earnings per share. On average, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.